Sachin Mani

TL;DR: A landscape of Shigella vaccine development efforts is provided, including live attenuated, formalin-killed whole-cell, glycoconjugate, subunit, and novel antigen vaccines (e.g., Type III secretion system and outer membrane proteins).

TL;DR: Observations from these studies demonstrate the low tumorigenic and oncogenic potential of the MDCK cell clone 9B9-1E4 and strongly suggest a high safety assurance level can be achieved through cell cloning and selection of low tumorigic andOncogenic cells for influenza vaccine production.

TL;DR: It is suggested that immune responses after ETEC infection involve traditional vaccine targets as well as a select number of more recently identified protein antigens that could offer additional avenues for vaccine development for these pathogens.

TL;DR: Key points are reviewed and research presented in each of the plenary conference sessions and poster presentations at the VASE Conference, aimed to accelerate communication and progress among those working in the enteric vaccine field to make Shigella and ETEC vaccines a reality as quickly as possible.

TL;DR: A serum bactericidal assay specific for three Shigella serotypes that measures killing of target bacteria at multiple serum dilutions and in the presence of exogenous complement is developed.